Avoro Capital Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Avoro Capital Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,430,455	Closed	-$454M	–	30
2026 Q1	$454M	Sell	11,430,455 -3,125,100	-21%	-$79.9M	4.47%	9
2025 Q4	$364M	Buy	14,555,555 +3,747,475	+35%	+$94.9M	3.58%	10
2025 Q3	$262M	Buy	10,808,080 +5,808,080	+116%	+$103M	3.39%	11
2025 Q2	$65.7M	Buy	5,000,000 +950,000	+23%	+$12M	1.15%	20
2025 Q1	$58.2M	Buy	+4,050,000	New	+$66.3M	0.91%	22
2021 Q3	–	Sell	-500,000	Closed	-$11.1M	–	50
2021 Q2	$11.1M	Buy	+500,000	New	+$11.8M	0.19%	41

Avoro Capital Advisors's CNTA Position: Q2 2026 in Review

Avoro Capital Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 11,430,455 shares — an estimated $454M sold.

Avoro Capital Advisors first reported a position in CNTA in Q2 2021 and held it in 6 quarters. The position peaked at $454M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Avoro Capital Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Avoro Capital Advisors sold 11,430,455 Centessa Pharmaceuticals shares in Q2 2026, an estimated $454M.
Avoro Capital Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 6 quarters.
Avoro Capital Advisors's Centessa Pharmaceuticals position peaked at $454M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.